{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:48:12Z","timestamp":1785041292713,"version":"3.55.0"},"reference-count":194,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.autrev.2025.103754","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T17:13:35Z","timestamp":1737393215000},"page":"103754","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders"],"prefix":"10.1016","volume":"24","author":[{"given":"Franz Felix","family":"Konen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"M\u00f6hn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Schefzyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Wiestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svjetlana","family":"Lovric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Hufendiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin Fritz","family":"Jendretzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gingele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Schwenkenbecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt-Wolfram","family":"S\u00fchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel A.","family":"Friese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Klotz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refik","family":"Pul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.autrev.2025.103754_bb0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103312","article-title":"Treatment of autoimmunity: the impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders","volume":"22","author":"Konen","year":"2023","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2025.103754_bb0010","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211039648","article-title":"Multiple sclerosis therapy consensus group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)","volume":"14","author":"Wiendl","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"8","key":"10.1016\/j.autrev.2025.103754_bb0015","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1056\/NEJMoa2201904","article-title":"Ublituximab versus teriflunomide in relapsing multiple sclerosis","volume":"387","author":"Steinman","year":"2022","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2025.103754_bb0020","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s40263-022-00939-9","article-title":"Efficacy and safety of multiple sclerosis drugs approved since 2018 and future developments","volume":"36","author":"Faissner","year":"2022","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0025","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"issue":"7\u20138","key":"10.1016\/j.autrev.2025.103754_bb0030","first-page":"23","article-title":"Receptor tyrosine kinase and tyrosine kinase inhibitors: new hope for success in multiple sclerosis therapy","volume":"11","author":"Mirshafiey","year":"2014","journal-title":"Innov Clin Neurosci"},{"issue":"8","key":"10.1016\/j.autrev.2025.103754_bb0035","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1111\/febs.16151","article-title":"AMPK in the brain: its roles in glucose and neural metabolism","volume":"289","author":"Muraleedharan","year":"2022","journal-title":"FEBS J"},{"issue":"5","key":"10.1016\/j.autrev.2025.103754_bb0040","doi-asserted-by":"crossref","DOI":"10.1002\/jcp.31230","article-title":"AMP-activated protein kinase as a mediator of mitochondrial dysfunction of multiple sclerosis in animal models: a systematic review","volume":"239","author":"Askari","year":"2024","journal-title":"J Cell Physiol"},{"issue":"21","key":"10.1016\/j.autrev.2025.103754_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111638","article-title":"The importance of phosphoinositide 3-kinase in neuroinflammation","volume":"25","author":"Wright","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2025.103754_bb0050","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.molimm.2019.03.015","article-title":"PI3K activity in dendritic cells exerts paradoxical effects during autoimmune inflammation","volume":"111","author":"Datler","year":"2019","journal-title":"Mol Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0055","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/187153009788452417","article-title":"The AKT axis as a therapeutic target in autoimmune diseases","volume":"9","author":"Wu","year":"2009","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"5","key":"10.1016\/j.autrev.2025.103754_bb0060","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1172\/JCI73411","article-title":"CaMK4-dependent activation of AKT\/mTOR and CREM-\u03b1 underlies autoimmunity-associated Th17 imbalance","volume":"124","author":"Koga","year":"2014","journal-title":"J Clin Invest"},{"issue":"15","key":"10.1016\/j.autrev.2025.103754_bb0065","doi-asserted-by":"crossref","first-page":"8077","DOI":"10.3390\/ijms23158077","article-title":"The mTOR signaling pathway in multiple sclerosis; from animal models to human data","volume":"23","author":"Vakrakou","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.autrev.2025.103754_bb0070","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1007\/s00415-012-6790-1","article-title":"Autoimmune disease in people with multiple sclerosis and their relatives: a systematic review and meta-analysis","volume":"260","author":"Dobson","year":"2013","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103754_bb0075","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.msard.2015.02.004","article-title":"Disease modifying therapies use associated with comorbid autoimmune diseases in multiple sclerosis patients","volume":"4","author":"Chouhfeh","year":"2015","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.autrev.2025.103754_bb0080","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/joim.12310","article-title":"The autoimmune spectrum of myasthenia gravis: a Swedish population-based study","volume":"277","author":"Fang","year":"2015","journal-title":"J Intern Med"},{"issue":"3","key":"10.1016\/j.autrev.2025.103754_bb0085","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1600-0404.1995.tb00432.x","article-title":"Associated autoimmune diseases in myasthenia gravis. A population-based study","volume":"91","author":"Christensen","year":"1995","journal-title":"Acta Neurol Scand"},{"issue":"7","key":"10.1016\/j.autrev.2025.103754_bb0090","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.4049\/jimmunol.1001228","article-title":"GATA2 and Spl positively regulate the c-kit promoter in mast cells","volume":"185","author":"Maeda","year":"2010","journal-title":"J Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103754_bb0095","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/ijc.23576","article-title":"KIT overexpression induces proliferation in astrocytes in an imatinib-responsive manner and associates with proliferation index in gliomas","volume":"123","author":"Blom","year":"2008","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0100","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4049\/jimmunol.1003603","article-title":"Kit (W-sh) mice develop earlier and more severe experimental autoimmune encephalomyelitis due to absence of immune suppression","volume":"187","author":"Li","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2025.103754_bb0105","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1471-2377-12-36","article-title":"Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study","volume":"12","author":"Vermersch","year":"2012","journal-title":"BMC Neurol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103754_bb0110","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1021\/acscombsci.0c00169","article-title":"Activity prediction of small molecule inhibitors for antirheumatoid arthritis targets based on artificial intelligence","volume":"22","author":"Xing","year":"2020","journal-title":"ACS Comb Sci"},{"issue":"10","key":"10.1016\/j.autrev.2025.103754_bb0115","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1080\/13543784.2020.1807934","article-title":"Inhibition of Bruton\u2019s tyrosine kinase as a novel therapeutic approach in multiple sclerosis","volume":"29","author":"Torke","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"3","key":"10.1016\/j.autrev.2025.103754_bb0120","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1021\/acs.jmedchem.0c01511","article-title":"Small-molecule kinase inhibitors for the treatment of nononcologic diseases","volume":"64","author":"Xie","year":"2021","journal-title":"J Med Chem"},{"issue":"37","key":"10.1016\/j.autrev.2025.103754_bb0125","doi-asserted-by":"crossref","first-page":"9839","DOI":"10.1021\/acs.jafc.0c03369","article-title":"Diaryl ether: a privileged scaffold for drug and agrochemical discovery","volume":"68","author":"Chen","year":"2020","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.autrev.2025.103754_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116358","article-title":"Progress in the development of small molecular inhibitors of the Bruton\u2019s tyrosine kinase (BTK) as a promising cancer therapy","volume":"47","author":"Liu","year":"2021","journal-title":"Bioorg Med Chem"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/BPL-200100","article-title":"Bruton\u2019s tyrosine kinase inhibition promotes myelin repair","volume":"5","author":"Martin","year":"2020","journal-title":"Brain Plast"},{"issue":"6","key":"10.1016\/j.autrev.2025.103754_bb0140","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/1381612827666210701152934","article-title":"Bruton\u2019s tyrosine kinase inhibition in the treatment of preclinical models and multiple sclerosis","volume":"28","author":"Steinmaurer","year":"2022","journal-title":"Curr Pharm Des"},{"issue":"9","key":"10.1016\/j.autrev.2025.103754_bb0145","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1474-4422(21)00250-7","article-title":"BTK inhibitors as potential therapies for multiple sclerosis","volume":"20","author":"Correale","year":"2021","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103754_bb0150","first-page":"2415","article-title":"JAK3: a novel JAK kinase associated with terminal differentiation of hematopoietic cells","volume":"9","author":"Rane","year":"1994","journal-title":"Oncogene"},{"key":"10.1016\/j.autrev.2025.103754_bb0155","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/gb-2004-5-12-253","article-title":"The Janus kinases (Jaks)","volume":"5","author":"Yamaoka","year":"2004","journal-title":"Genome Biol"},{"key":"10.1016\/j.autrev.2025.103754_bb0160","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1387-2656(06)12006-2","article-title":"Inhibitors of signal transduction protein kinases as targets for cancer therapy","volume":"12","author":"Mikalsen","year":"2006","journal-title":"Biotechnol Annu Rev"},{"issue":"7","key":"10.1016\/j.autrev.2025.103754_bb0165","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s00018-008-8539-7","article-title":"Therapeutic protein kinase inhibitors","volume":"66","author":"Grant","year":"2009","journal-title":"Cell Mol Life Sci"},{"issue":"2\u20133","key":"10.1016\/j.autrev.2025.103754_bb0170","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0163-7258(98)00066-7","article-title":"Protein tyrosine kinase inhibitors as novel therapeutic agents","volume":"82","author":"Levitzki","year":"1999","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.autrev.2025.103754_bb0175","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1359-6446(03)03014-9","article-title":"Inhibitors of JAKs\/STATs and the kinases: a possible new cluster of drugs","volume":"9","author":"Luo","year":"2004","journal-title":"Drug Discov Today"},{"issue":"12","key":"10.1016\/j.autrev.2025.103754_bb0180","article-title":"Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients","volume":"12","author":"Hahn","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"10.1016\/j.autrev.2025.103754_bb0185","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: a review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.autrev.2025.103754_bb0190","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jamaoncol.2016.4975","article-title":"Androgen receptor function and androgen receptor-targeted therapies in breast cancer: a review","volume":"3","author":"Kono","year":"2017","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0195","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s13075-023-03181-w","article-title":"Mechanistic target of rapamycin (mTOR): a potential new therapeutic target for rheumatoid arthritis","volume":"25","author":"Zhang","year":"2023","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2025.103754_bb0200","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7684352","article-title":"Low-dose sirolimus immunoregulation therapy in patients with active rheumatoid arthritis: a 24-week follow-up of the randomized, open-label, parallel-controlled trial","volume":"2019","author":"Wen","year":"2019","journal-title":"J Immunol Res"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0205","first-page":"58","article-title":"Sirolimus selectively increases circulating Treg cell numbers and restores the Th17\/Treg balance in rheumatoid arthritis patients with low disease activity or in DAS28 remission who previously received conventional disease-modifying anti-rheumatic drugs","volume":"38","author":"Niu","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103754_bb0210","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/ard.2007.078808","article-title":"Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study","volume":"67","author":"Bruyn","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.autrev.2025.103754_bb0215","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/rheumatology\/keaa410","article-title":"A phase 2 randomized, double-blind, placebo-controlled, proof-of-concept study of oral seletalisib in primary Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Juarez","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.autrev.2025.103754_bb0220","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s43440-019-00019-8","article-title":"Metformin accelerates myelin recovery and ameliorates behavioral deficits in the animal model of multiple sclerosis via adjustment of AMPK\/Nrf2\/mTOR signaling and maintenance of endogenous oligodendrogenesis during brain self-repairing period","volume":"72","author":"Sanadgol","year":"2020","journal-title":"Pharmacol Rep"},{"issue":"3","key":"10.1016\/j.autrev.2025.103754_bb0225","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/cns.13791","article-title":"Liraglutide attenuate central nervous inflammation and demyelination through AMPK and pyroptosis-related NLRP3 pathway","volume":"28","author":"Song","year":"2022","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.autrev.2025.103754_bb0230","article-title":"Methylprednisolone modulates the Tfr\/Tfh ratio in EAE-induced neuroinflammation through the PI3K\/AKT\/FoxO1 and PI3K\/AKT\/mTOR signalling pathways","author":"Wu","year":"2024","journal-title":"Inflammation"},{"issue":"11","key":"10.1016\/j.autrev.2025.103754_bb0235","first-page":"1151","article-title":"PI3K isoforms as drug targets in inflammatory diseases: lessons from pharmacological and genetic strategies","volume":"10","author":"Harris","year":"2009","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.autrev.2025.103754_bb0240","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1362629","article-title":"A metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration (MACSiMiSE-BRAIN): study protocol for a multi-center randomized placebo controlled clinical trial","volume":"15","author":"De Keersmaecker","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0250","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/cmdc.200600221","article-title":"Discovery of selective irreversible inhibitors for Bruton\u2019s tyrosine kinase","volume":"2","author":"Pan","year":"2007","journal-title":"ChemMedChem"},{"issue":"6","key":"10.1016\/j.autrev.2025.103754_bb0255","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1021\/acs.jmedchem.7b01712","article-title":"Discovery of GDC-0853: a potent, selective, and noncovalent Bruton\u2019s tyrosine kinase inhibitor in early clinical development","volume":"61","author":"Crawford","year":"2018","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.autrev.2025.103754_bb0260","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton\u2019s tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0270","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40268-024-00468-4","article-title":"Comparative CNS pharmacology of the Bruton\u2019s tyrosine kinase (BTK) inhibitor tolebrutinib versus other BTK inhibitor candidates for treating multiple sclerosis","volume":"24","author":"Turner","year":"2024","journal-title":"Drugs R D"},{"issue":"11","key":"10.1016\/j.autrev.2025.103754_bb0275","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S1474-4422(24)00328-4","article-title":"Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials","volume":"23","author":"Montalban","year":"2024","journal-title":"Lancet Neurol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103754_bb0280","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1111\/cts.13407","article-title":"Determination of a clinically effective evobrutinib dose: exposure-response analyses of a phase II relapsing multiple sclerosis study","volume":"15","author":"Papasouliotis","year":"2022","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.autrev.2025.103754_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103001","article-title":"Concentration of evobrutinib, a BTK inhibitor, in cerebrospinal fluid during treatment of patients with relapsing multiple sclerosis in a phase 2 study","volume":"51","author":"Piasecka-Stryczynska","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.autrev.2025.103754_bb0290","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2025.103754_bb0295","series-title":"Efficacy and Safety of tolebrutinib Versus teriflunomide in Relapsing Multiple Sclerosis: Results From the Phase 3 GEMINI 1 and 2 Trials","author":"Oh","year":"2024"},{"key":"10.1016\/j.autrev.2025.103754_bb0300","series-title":"Efficacy and Safety of Tolebrutinib Versus Placebo in Non-Relapsing Secondary Progressive Multiple Sclerosis: Results From the Phase 3 HERCULES Trial","author":"Fox","year":"2024"},{"issue":"10","key":"10.1016\/j.autrev.2025.103754_bb0305","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2147\/ITT.S288550","article-title":"Bruton\u2019s tyrosine kinase inhibition for the treatment of rheumatoid arthritis","author":"Arneson","year":"2021","journal-title":"Immunotargets Ther"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0310","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.113.203489","article-title":"Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans","volume":"346","author":"Evans","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0315","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/cts.12713","article-title":"Safety, tolerability, pharmacokinetics, target occupancy, and concentration-QT analysis of the novel BTK inhibitor evobrutinib in healthy volunteers","volume":"13","author":"Becker","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0320","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1124\/jpet.119.257089","article-title":"Absence of pharmacokinetic interactions between the Bruton\u2019s tyrosine kinase inhibitor fenebrutinib and methotrexate","volume":"371","author":"Jones","year":"2019","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0325","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40744-019-00182-7","article-title":"Spebrutinib (CC-292) affects markers of B cell activation, chemotaxis, and osteoclasts in patients with rheumatoid arthritis: results from a mechanistic study","volume":"7","author":"Schafer","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"9","key":"10.1016\/j.autrev.2025.103754_bb0330","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/art.41275","article-title":"Fenebrutinib versus placebo or adalimumab in rheumatoid arthritis: a randomized, double-blind, phase II trial (ANDES study)","volume":"72","author":"Cohen","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103754_bb0335","doi-asserted-by":"crossref","first-page":"969","DOI":"10.3899\/jrheum.200893","article-title":"Safety and efficacy of poseltinib, Bruton\u2019s tyrosine kinase inhibitor, in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled, 2-part phase II study","volume":"48","author":"Genovese","year":"2021","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103754_bb0340","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1136\/annrheumdis-2019-216588","article-title":"Salivary gland epithelial cells from patients with Sj\u00f6gren\u2019s syndrome induce B-lymphocyte survival and activation","volume":"79","author":"Rivi\u00e8re","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.autrev.2025.103754_bb0345","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1111\/cts.13005","article-title":"Remibrutinib (LOU064): a selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial","volume":"14","author":"Kaul","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"10","key":"10.1016\/j.autrev.2025.103754_bb0350","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1021\/acs.jmedchem.0c00597","article-title":"A fast and clean BTK inhibitor","volume":"63","author":"Gabizon","year":"2020","journal-title":"J Med Chem"},{"issue":"8","key":"10.1016\/j.autrev.2025.103754_bb0355","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s40265-020-01318-8","article-title":"Tirabrutinib: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.autrev.2025.103754_bb0360","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/cpt.1056","article-title":"Safety, pharmacokinetics, and pharmacodynamics in healthy volunteers treated with GDC-0853, a selective reversible Bruton\u2019s tyrosine kinase inhibitor","volume":"103","author":"Herman","year":"2018","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.autrev.2025.103754_bb0365","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/art.41811","article-title":"Efficacy, safety, and pharmacodynamic effects of the bruton\u2019s tyrosine kinase inhibitor fenebrutinib (GDC-0853) in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled trial","volume":"73","author":"Isenberg","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0370","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/acr2.11511","article-title":"Efficacy and safety of the Bruton\u2019s tyrosine kinase inhibitor Evobrutinib in systemic lupus erythematosus: results of a phase II, randomized, double-blind, placebo-controlled dose-ranging trial","volume":"5","author":"Wallace","year":"2023","journal-title":"ACR Open Rheumatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0375","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40257-022-00751-7","article-title":"Review of an anti-CD20 monoclonal antibody for the treatment of autoimmune diseases of the skin","volume":"24","author":"Ly","year":"2023","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.autrev.2025.103754_bb0380","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coph.2019.01.001","article-title":"Pharmacological advances in pemphigus","volume":"46","author":"Bilgic Temel","year":"2019","journal-title":"Curr Opin Pharmacol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103754_bb0385","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/bjd.20431","article-title":"Proof of concept for the clinical effects of oral rilzabrutinib, the first Bruton tyrosine kinase inhibitor for pemphigus vulgaris: the phase II BELIEVE study","volume":"185","author":"Murrell","year":"2021","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2025.103754_bb0390","article-title":"Bruton tyrosine kinase inhibition and its role as an emerging treatment in pemphigus","volume":"8","author":"Patsatsi","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.autrev.2025.103754_bb0400","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jdermsci.2021.07.002","article-title":"A multicenter, open-label, uncontrolled, single-arm phase 2 study of tirabrutinib, an oral Bruton\u2019s tyrosine kinase inhibitor, in pemphigus","volume":"103","author":"Yamagami","year":"2021","journal-title":"J Dermatol Sci"},{"issue":"12","key":"10.1016\/j.autrev.2025.103754_bb0405","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.3390\/cells9122627","article-title":"Skin-associated B cells in the pathogenesis of cutaneous autoimmune diseases-implications for therapeutic approaches","volume":"9","author":"Fetter","year":"2020","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.autrev.2025.103754_bb0410","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/j.jaci.2022.08.027","article-title":"Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria","volume":"150","author":"Maurer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.autrev.2025.103754_bb0415","article-title":"Remibrutinib demonstrates favorable safety profile and sustained efficacy in chronic spontaneous urticaria over 52 weeks","author":"Jain","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103754_bb0420","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1136\/ard.2011.151522","article-title":"Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial","volume":"70","author":"Taylor","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2025.103754_bb0425","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.840238","article-title":"Case report: rapid desensitization to ocrelizumab for multiple sclerosis is effective and safe","volume":"13","author":"Aun","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0430","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000661","article-title":"Refractory chronic spontaneous urticaria after the use of alemtuzumab in multiple sclerosis","volume":"7","author":"Hu","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0435","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1182\/hematology.2020000118","article-title":"Managing toxicities of Bruton tyrosine kinase inhibitors","volume":"2020","author":"Lipsky","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.autrev.2025.103754_bb0440","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.630942","article-title":"Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects","volume":"9","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103754_bb0445","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.autrev.2025.103754_bb0450","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1056\/NEJMoa1112072","article-title":"Tofacitinib or adalimumab versus placebo in rheumatoid arthritis","volume":"367","author":"van Vollenhoven","year":"2012","journal-title":"N Engl J Med"},{"issue":"9865","key":"10.1016\/j.autrev.2025.103754_bb0455","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0140-6736(12)61424-X","article-title":"Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial","volume":"381","author":"Burmester","year":"2013","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.autrev.2025.103754_bb0460","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","article-title":"Tofacitinib versus methotrexate in rheumatoid arthritis","volume":"370","author":"Lee","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.autrev.2025.103754_bb0465","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1056\/NEJMoa1507247","article-title":"Baricitinib in patients with refractory rheumatoid arthritis","volume":"374","author":"Genovese","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.autrev.2025.103754_bb0470","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"issue":"10139","key":"10.1016\/j.autrev.2025.103754_bb0475","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1016\/S0140-6736(18)31115-2","article-title":"Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Burmester","year":"2018","journal-title":"Lancet"},{"issue":"10139","key":"10.1016\/j.autrev.2025.103754_bb0480","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1016\/S0140-6736(18)31116-4","article-title":"Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial","volume":"391","author":"Genovese","year":"2018","journal-title":"Lancet"},{"issue":"10188","key":"10.1016\/j.autrev.2025.103754_bb0485","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1016\/S0140-6736(19)30419-2","article-title":"Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study","volume":"393","author":"Smolen","year":"2019","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.autrev.2025.103754_bb0490","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","article-title":"Trial of upadacitinib or abatacept in rheumatoid arthritis","volume":"383","author":"Rubbert-Roth","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2025.103754_bb0495","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"issue":"10315","key":"10.1016\/j.autrev.2025.103754_bb0500","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0505","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s13075-021-02590-z","article-title":"Patient- and physician-reported outcomes from two phase 3 randomized studies (RAJ3 and RAJ4) of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis","volume":"23","author":"Tanaka","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0510","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.38949","article-title":"A randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active rheumatoid arthritis","volume":"67","author":"Fleischmann","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0515","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/art.39473","article-title":"VX-509 (Decernotinib), an oral selective JAK-3 inhibitor, in combination with methotrexate in patients with rheumatoid arthritis","volume":"68","author":"Genovese","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103754_bb0520","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.autrev.2025.103754_bb0525","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.autrev.2025.103754_bb0530","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"21","key":"10.1016\/j.autrev.2025.103754_bb0535","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.autrev.2025.103754_bb0540","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103754_bb0545","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology"},{"issue":"10066","key":"10.1016\/j.autrev.2025.103754_bb0550","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"issue":"10292","key":"10.1016\/j.autrev.2025.103754_bb0555","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet"},{"issue":"7 Suppl 2","key":"10.1016\/j.autrev.2025.103754_bb0560","first-page":"6","article-title":"Efficacy and safety of deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, in patients with moderately to severely active ulcerative colitis: 12-week results from the phase 2 LATTICE-UC study","volume":"18","year":"2022","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0565","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: a phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J Dermatol Sci"},{"issue":"16","key":"10.1016\/j.autrev.2025.103754_bb0570","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.autrev.2025.103754_bb0575","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0580","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","volume":"88","author":"Armstrong","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0585","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jaad.2022.08.061","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial","volume":"88","author":"Strober","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"10162","key":"10.1016\/j.autrev.2025.103754_bb0590","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/S0140-6736(18)32483-8","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Mease","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0595","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2022.03.059","article-title":"Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study","volume":"87","author":"Tehlirian","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103754_bb0600","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1016\/j.jid.2020.03.962","article-title":"TYK2\/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis: phase IIa, randomized, double-blind, placebo-controlled trial","volume":"140","author":"Forman","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103754_bb0605","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/jcph.1046","article-title":"The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2\/JAK1 inhibitor (PF-06700841) in healthy subjects and patients with plaque psoriasis","volume":"58","author":"Banfield","year":"2018","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0610","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/bjd.16004","article-title":"Efficacy and safety of the Janus kinase 1 inhibitor PF-04965842 in patients with moderate-to-severe psoriasis: phase II, randomized, double-blind, placebo-controlled study","volume":"179","author":"Schmieder","year":"2018","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0615","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12895-016-0051-4","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial","volume":"16","author":"Papp","year":"2016","journal-title":"BMC Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103754_bb0620","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103754_bb0625","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1111\/bjd.14399","article-title":"Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103754_bb0630","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3109\/09546634.2015.1115819","article-title":"A randomized, double-blind, placebo-controlled, dose-escalation study of the safety and efficacy of INCB039110, an oral janus kinase 1 inhibitor, in patients with stable, chronic plaque psoriasis","volume":"27","author":"Bissonnette","year":"2016","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0635","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/jdv.12081","article-title":"Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis","volume":"28","author":"Mamolo","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103754_bb0640","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.autrev.2025.103754_bb0645","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","article-title":"Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study","volume":"76","author":"van der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.autrev.2025.103754_bb0650","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1093\/rheumatology\/key104","article-title":"Tofacitinib is associated with attainment of the minimally important reduction in axial magnetic resonance imaging inflammation in ankylosing spondylitis patients","volume":"57","author":"Maksymowych","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"10214","key":"10.1016\/j.autrev.2025.103754_bb0655","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0660","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12967-016-1050-2","article-title":"A proof-of-concept study with the tyrosine kinase inhibitor nilotinib in spondyloarthritis","volume":"14","author":"Paramarta","year":"2016","journal-title":"J Transl Med"},{"issue":"10162","key":"10.1016\/j.autrev.2025.103754_bb0665","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial","volume":"392","author":"van der Heijde","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.autrev.2025.103754_bb0670","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jaad.2018.01.018","article-title":"Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study","volume":"80","author":"Guttman-Yassky","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0675","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","article-title":"Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial","volume":"86","author":"Blauvelt","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"10290","key":"10.1016\/j.autrev.2025.103754_bb0680","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"issue":"10290","key":"10.1016\/j.autrev.2025.103754_bb0685","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.autrev.2025.103754_bb0690","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"JADE COMPARE investigators. Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.autrev.2025.103754_bb0695","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0700","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jaci.2019.08.042","article-title":"Treatment of atopic dermatitis with ruxolitinib cream (JAK1\/JAK2 inhibitor) or triamcinolone cream","volume":"145","author":"Kim","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103754_bb0705","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1111\/bjd.18469","article-title":"Efficacy and safety of topical delgocitinib in patients with chronic hand eczema: data from a randomized, double-blind, vehicle-controlled phase IIa study","volume":"182","author":"Worm","year":"2020","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103754_bb0710","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.jaci.2019.07.013","article-title":"Oral Janus kinase\/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis","volume":"144","author":"Pavel","year":"2019","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103754_bb0715","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/bjd.17932","article-title":"The oral Janus kinase\/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study","volume":"181","author":"Bissonnette","year":"2019","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103754_bb0720","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40257-021-00627-2","article-title":"Efficacy and safety of SHR0302, a highly selective Janus kinase 1 inhibitor, in patients with moderate to severe atopic dermatitis: a phase II randomized clinical trial","volume":"22","author":"Zhao","year":"2021","journal-title":"Am J Clin Dermatol"},{"issue":"18","key":"10.1016\/j.autrev.2025.103754_bb0725","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","article-title":"Two phase 3 trials of baricitinib for alopecia areata","volume":"386","author":"King","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.autrev.2025.103754_bb0730","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jaad.2021.05.050","article-title":"Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: phase 2 results from a randomized controlled study","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103754_bb0735","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1080\/13543784.2021.2012149","article-title":"Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata","volume":"30","author":"Eisman","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"10.1016\/j.autrev.2025.103754_bb0740","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/j.jaci.2021.10.036","article-title":"Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers","volume":"149","author":"Guttman-Yassky","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0745","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jaad.2021.12.008","article-title":"Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial","volume":"87","author":"Peeva","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.autrev.2025.103754_bb0750","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/jdv.17909","article-title":"Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib","volume":"36","author":"Winnette","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0755","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0770","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13075-022-02794-x","article-title":"Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial","volume":"24","author":"D\u00f6rner","year":"2022","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0775","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0780","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000424","article-title":"Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways","volume":"7","author":"D\u00f6rner","year":"2020","journal-title":"Lupus Sci Med"},{"issue":"10143","key":"10.1016\/j.autrev.2025.103754_bb0785","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","article-title":"Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"392","author":"Wallace","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2025.103754_bb0790","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1136\/annrheumdis-2022-eular.1968","article-title":"POS0190 efficacy and safety of baricitinib in patients with systemic lupus erythematosus: results from two randomised, double-blind, placebo-controlled, parallel-group, phase 3 studies","volume":"81","author":"Morand","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0795","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/art.42391","article-title":"Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: a phase II, randomized, double-blind, placebo-controlled trial","volume":"75","author":"Morand","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103754_bb0805","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001490","article-title":"Phase II, randomised, double-blind, multicentre study evaluating the safety and efficacy of filgotinib and lanraplenib in patients with lupus membranous nephropathy","volume":"6","author":"Baker","year":"2020","journal-title":"RMD Open"},{"issue":"13","key":"10.1016\/j.autrev.2025.103754_bb0810","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1177\/0961203316640910","article-title":"Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus","volume":"25","author":"Kahl","year":"2016","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.autrev.2025.103754_bb0815","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1177\/0961203315573347","article-title":"DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184","volume":"24","author":"van Vollenhoven","year":"2015","journal-title":"Lupus"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0820","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0825","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00408-021-00436-8","article-title":"Tofacitinib as a steroid-sparing therapy in pulmonary sarcoidosis, an open-label prospective proof-of-concept study","volume":"199","author":"Friedman","year":"2021","journal-title":"Lung"},{"issue":"12","key":"10.1016\/j.autrev.2025.103754_bb0830","doi-asserted-by":"crossref","first-page":"4797","DOI":"10.1093\/rheumatology\/keac167","article-title":"Safety and efficacy of filgotinib, lanraplenib and tirabrutinib in Sj\u00f6gren\u2019s syndrome: a randomized, phase 2, double-blind, placebo-controlled study","volume":"61","author":"Price","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0835","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000328","article-title":"Ruxolitinib treatment in a patient with neuromyelitis optica: a case report","volume":"4","author":"Hodecker","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"6","key":"10.1016\/j.autrev.2025.103754_bb0840","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15477","article-title":"New developing multiple sclerosis in a patient using tofacitinib due to alopesia areata","volume":"35","author":"Er\u00e7oban","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.autrev.2025.103754_bb0845","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102568","article-title":"CNS demyelination during tofacitinib therapy: first report","volume":"46","author":"Massoud","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"10.1016\/j.autrev.2025.103754_bb0850","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001148","article-title":"Efficacy and safety of masitinib in progressive forms of multiple sclerosis: a randomized, phase 3, clinical trial","volume":"9","author":"Vermersch","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"3","key":"10.1016\/j.autrev.2025.103754_bb0855","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar2740","article-title":"Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study","volume":"11","author":"Tebib","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"10.1016\/j.autrev.2025.103754_bb0860","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S2213-8587(21)00139-X","article-title":"Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Gitelman","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103754_bb0865","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"12","key":"10.1016\/j.autrev.2025.103754_bb0870","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1002\/art.38851","article-title":"Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"66","author":"Weinblatt","year":"2014","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.autrev.2025.103754_bb0875","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2340\/00015555-2047","article-title":"Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis","volume":"95","author":"Roblin","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"11","key":"10.1016\/j.autrev.2025.103754_bb0880","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/exd.14253","article-title":"Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: a double-blind phase Ib study","volume":"30","author":"Walker","year":"2021","journal-title":"Exp Dermatol"},{"issue":"15 Supplement","key":"10.1016\/j.autrev.2025.103754_bb0885","article-title":"Nilotinib-associated demyelinating disease (P2.2-093)","volume":"92","author":"Judge","year":"2019","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.autrev.2025.103754_bb0890","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/1352458519892914","article-title":"CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: a report of two cases","volume":"26","author":"Rotstein","year":"2020","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2025.103754_bb0895","doi-asserted-by":"crossref","DOI":"10.1136\/jnnp-2016-315106.154","article-title":"CNS demyelination in patients on nilotinib treatment for CML","volume":"87","author":"Rekhi","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"13","key":"10.1016\/j.autrev.2025.103754_bb0900","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1080\/10428194.2019.1633635","article-title":"Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series","volume":"60","author":"Rafei","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.autrev.2025.103754_bb0905","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12185-017-2339-5","article-title":"Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia","volume":"107","author":"Ishida","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.autrev.2025.103754_bb0910","article-title":"Resolution of crizotinib-associated fulminant hepatitis following cessation of treatment. Case reports","volume":"2018","author":"Charville","year":"2018","journal-title":"Hepatol"},{"issue":"36","key":"10.1016\/j.autrev.2025.103754_bb0915","doi-asserted-by":"crossref","first-page":"10475","DOI":"10.3748\/wjg.v21.i36.10475","article-title":"Autoimmune-like hepatitis during masitinib therapy in an amyotrophic lateral sclerosis patient","volume":"21","author":"Salvado","year":"2015","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.autrev.2025.103754_bb0920","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/COC.0b013e31802b4ef7","article-title":"An acute hepatitis resembling autoimmune hepatitis occurring during imatinib therapy in a gastrointestinal stromal tumor patient","volume":"32","author":"Aliberti","year":"2009","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.autrev.2025.103754_bb0925","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10245330600937929","article-title":"Imatinib-induced immune hepatitis: case report and literature review","volume":"12","author":"Al Sobhi","year":"2007","journal-title":"Hematology"},{"issue":"5","key":"10.1016\/j.autrev.2025.103754_bb0930","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1016\/j.jaad.2012.01.034","article-title":"Erlotinib-induced bullous pemphigoid","volume":"67","author":"Stingeni","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.autrev.2025.103754_bb0935","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jdcr.2019.07.028","article-title":"Bullous pemphigoid associated with nintedanib","volume":"5","author":"Hasson","year":"2019","journal-title":"JAAD Case Rep"},{"issue":"3","key":"10.1016\/j.autrev.2025.103754_bb0950","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000208006","article-title":"Adverse events associated with disease-modifying drugs for multiple sclerosis: a multiregional population-based study","volume":"102","author":"Ng","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103754_bb0955","article-title":"Hypogammaglobulinemia and severe infections in multiple sclerosis patients on anti-CD20 agents: a multicentre study","volume":"93","author":"Smolik","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.autrev.2025.103754_bb0960","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1080\/03007995.2023.2256220","article-title":"The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis","volume":"39","author":"Butzkueven","year":"2023","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.autrev.2025.103754_bb0965","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105830","article-title":"Safety of high efficacy therapies in older people with multiple sclerosis: a real-world evidence study","volume":"90","author":"Silva","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.autrev.2025.103754_bb0970","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/WNF.0000000000000598","article-title":"Real-world effectiveness and safety of cladribine in multiple sclerosis: longitudinal data from the nationwIDE registry in Argentina","volume":"47","author":"Rojas","year":"2024","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"10.1016\/j.autrev.2025.103754_bb0975","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1212\/WNL.0000000000002441","article-title":"Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study","volume":"86","author":"O\u2019Connor","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2025.103754_bb0980","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105015","article-title":"Prevalence of 2-year \u201cno evidence of disease activity\u201d (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study","volume":"79","author":"Bazzurri","year":"2023","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.autrev.2025.103754_bb0985","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209574","article-title":"Association of clinical relapses with disease outcomes in multiple sclerosis patients older than 50 years","volume":"103","author":"Pfeuffer","year":"2024","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.autrev.2025.103754_bb0990","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1474-4422(23)00154-0","article-title":"Risk of new disease activity in patients with multiple sclerosis who continue or discontinue disease-modifying therapies (DISCOMS): a multicentre, randomised, single-blind, phase 4, non-inferiority trial","volume":"22","author":"Corboy","year":"2023","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.autrev.2025.103754_bb0995","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N Engl J Med"},{"issue":"10127","key":"10.1016\/j.autrev.2025.103754_bb1000","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.autrev.2025.103754_bb1005","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1001\/jamaneurol.2024.2920","article-title":"Comorbidity and disease activity in multiple sclerosis","volume":"81","author":"Salter","year":"2024","journal-title":"JAMA Neurol"},{"issue":"7","key":"10.1016\/j.autrev.2025.103754_bb1010","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41573-021-00195-4","article-title":"Kinase drug discovery 20 years after imatinib: progress and future directions","volume":"20","author":"Cohen","year":"2021","journal-title":"Nat Rev Drug Discov"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722500014X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899722500014X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,2]],"date-time":"2025-03-02T13:37:27Z","timestamp":1740922647000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899722500014X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":194,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S156899722500014X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103754","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2025.103754","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103754"}}